Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?

por Dekkers, Claire C J, Gansevoort, Ron T
Publicado 2020

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors

por Dekkers, Claire C. J., Gansevoort, Ron T., Heerspink, Hiddo J. L.
Publicado 2018

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers

por Dekkers, Claire C. J., Petrykiv, Sergei, Laverman, Gozewijn D., Cherney, David Z., Gansevoort, Ron T., Heerspink, Hiddo J. L.
Publicado 2018

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

por Dekkers, Claire C J, Wheeler, David C, Sjöström, C David, Stefansson, Bergur V, Cain, Valerie, Heerspink, Hiddo J L
Publicado 2018

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

por Dekkers, Claire C J, Wheeler, David C, Sjöström, C David, Stefansson, Bergur V, Cain, Valerie, Heerspink, Hiddo J L
Publicado 2018

Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes

por Dekkers, Claire C. J., Sjöström, C. David, Greasley, Peter J., Cain, Valerie, Boulton, David W., Heerspink, Hiddo J. L.
Publicado 2019

The Value of Pre-Ablative I-131 Scan for Clinical Management in Patients With Differentiated Thyroid Carcinoma

por van der Boom, Trynke, Zandee, Wouter T., Dekkers, Claire C. J., van der Horst-Schrivers, Anouk N. A., Jansen, Liesbeth, Kruijff, Schelto, Brouwers, Adrienne H., Links, Thera P.
Publicado 2021

Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors

por Eickhoff, Mie K., Dekkers, Claire C. J., Kramers, Bart J., Laverman, Gozewijn Dirk, Frimodt-Møller, Marie, Jørgensen, Niklas Rye, Faber, Jens, Danser, A. H. Jan, Gansevoort, Ron T., Rossing, Peter, Persson, Frederik, Heerspink, Hiddo J. L.
Publicado 2019

Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND

por Sen, Taha, Scholtes, Rosalie, Greasley, Peter J., Cherney, David Z. I., Dekkers, Claire C. J., Vervloet, Marc, Danser, Alexander H. J., Barbour, Sean J., Karlsson, Cecilia, Hammarstedt, Ann, Li, Qiang, Laverman, Gozewijn D., Bjornstad, Petter, van Raalte, Daniel H., Heerspink, Hiddo J. L.
Publicado 2022

Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease

por van der Aart-van der Beek, Annemarie B., Koomen, Jeroen V., Dekkers, Claire C. J., Barbour, Sean J., Boulton, David W., Gansevoort, Ron T., Greasley, Peter J., Abdul Gafor, Abdul Halim, Laverman, Gozewijn D., Li, Qiang, Lim, Soo Kun, Stevens, Jasper, Vervloet, Marc G., Singh, Sunita, Cattran, Daniel C., Reich, Heather N., Cherney, David Z. I., Heerspink, Hiddo J. L.
Publicado 2021